Wednesday, July 27, 2016 10:18:18 AM
Pipeline is worth Billions
Realy undervalued at 9 dollar
So much going on.
Here's Some highlights from S.A.
2016 VALUE DRIVERS & MILESTONES
(2nd-Half of 2016 is packed with VALUE DRIVING MILESTONES for INO, imo.)
1. ( MOST IMPORTANT ) Launch PHASE 3 VGX-3100 for Cervical Dysplasia
• Huge Milestone & INO could highly likely REPLICATE successful results from P2 again in P3, imo
• Post-Hoc Analysis showed most responders were COMPLETE RESPONDERS / COMPLETE REMISSIONS
• I like to see this milestone put a footing on INO's PPS at $40, imo
2. Launch VGX-3112 + Checkpoint Inhibitors (MEDI) COMBO for Cervical Cancer
• INO & MEDI seems to be focused on expedited path to approval, imo
• This can be a huge milestone & likely trigger significant amount of milestone payment, imo
3. ( MOST EXCITING NEW TRIAL ) Launch INO-5400 "Universal" Cancer Vaccine w/ Checkpoint Inhibitors
• INO is confident enough to go after one of the fastest progressing cancer indications after diagnosis w/ no alternatives, imo
• May strike MONUMENTAL SIZE new PARTNERSHIP/S, imo
4. ( MOST EXCITING MILESTONE ) Report Phase 1 INO-1400 hTERT "UNIVERSAL" Cancer Vaccine
interim data
• If the results are good, there can be huge partnership/s or buy-out FRENZY, imo
• hTERT cancer vaccine can be applicable to 85% of ALL cancers & allow INO to OWN the most comprehensive immino-oncology COMBO therapies, imo
• In general, INO sees hTERT as being a foundation antigen in multiple immunotherapies combining different antigens and checkpoint inhibitors.
• Expanded Cancer Indications to Total of 9 Tumor Types :
Original Umbrella Trials :
1. Pancreatic Cancer
2. Lung Cancer
3. Breast Cancer
Recently Expanded Trials :
4. Head & Neck Squamous Cell Cancer
5. Ovarian Cancer
6. Colorectal Cancer
7. Gastric Cancer
8. Heptocellular Cancer
9. Esophageal Cancer
*** If the Phase 1 data is positive, INO probably can make it work by combining its own DNA-based Immune Activators ( i,e DNA IL-12 ) + its own DNA-based Checkpoint Inhibitors ( to be unveiled in 2017 ) or with its collaborators' Checkpoint Inhibitors, imo
*** Seems like INO is liking what they are seeing from the "Open-Label" Phase 1 Human Trials to be expanding to 9 tumor types, imo.
5. Report INO 5150 for Prostate Cancer
• If the results are good, INO can strike another partnership for significant amount of money, imo
6. REPORTED SUCCESSFUL Ebola HUMAN Study results
• Achieved 100% Response rate ( via Skin EP )
• Achieved 100% Response rate ( via Intra-Muscular EP w/ DNA IL12 adjuvant )
••• Great indication INO can succeed Zika vaccine w/ similar fashion (100%), imo
••• Great indication INO can take chunk of the $50+ Billion ( estimated by 2019) Infectious Disease Vaccine Market, imo.
7. Zika can be the WILDCARD for INO in 2016
• Breezed through Vaccine Design & Pre-Clinical ( Small & Large Non-Human Primate Animals ) w/ 100% protection in just about 6 months.
• Received approval for first-in-man Zika vaccine clinical trial from FDA.
, Estimated to report interim data from Phase 1 HUMAN Trial later in 2016
• If things get desperate in U.S. this summer, FDA may invoke ANIMAL RULE, imo
• May strike PRV deal( worth between $100Million to $300+M), imo
Recent INO News
- INOVIO to Present at Upcoming Scientific Conference • PR Newswire (US) • 09/17/2024 08:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/13/2024 10:22:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:06:54 AM
- INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 • PR Newswire (US) • 07/25/2024 08:05:00 PM
- INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 • PR Newswire (US) • 07/25/2024 12:00:00 PM
- INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway • PR Newswire (US) • 07/11/2024 12:00:00 PM
- INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer • PR Newswire (US) • 07/02/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 07/01/2024 08:00:00 PM
- INOVIO Added to Russell 2000® Index Effective July 1, 2024 • PR Newswire (US) • 07/01/2024 12:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc. • PR Newswire (US) • 06/04/2024 12:00:00 PM
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/31/2024 08:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:49:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:13:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:11:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:10:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM